Assessment and Localisation of Response to Primary Systemic Therapy in Breast Cancer

被引：1

作者：

Noble, Frith ^{[1
]}

机构：

[1] Wishaw Gen Hosp, Radiol Dept, 50 Netherton St, Wishaw ML2 0DP, Scotland

来源：

ULTRASOUND | 2009年 / 17卷 / 02期

关键词：

Primary Systemic Therapy; Ultrasound Guided Marking;

D O I：

10.1179/174313409X415819

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Primary systemic therapy (PST) is used in non-metastatic breast cancer to decrease tumour size and reduce the extent of surgery. This article reviews imaging and surgical issues associated with the increasing use of PST in the management of breast cancer. The role of imaging, with a special focus on ultrasound, is evaluated.

引用

页码：80 / 84

页数：5

共 50 条

[31] Omitting axillary lymph node dissection in breast cancer patients with extensive nodal disease and excellent response to primary systemic therapy using the MARI protocol
van Hemert, Annemiek K. E.
van Loevezijn, Ariane A.
Baas, Marie-Sophie P. D.
Stokkel, Marcel P. M.
Groen, Emma J.
van der Noort, Vincent
Loo, Claudette E.
Sonke, Gabe S.
Russell, Nicola
van Duijnhoven, Frederieke H.
Peeters, Marie-Jeanne T. F. D. Vrancken
BREAST, 2025, 80
[32] Past, present and future of primary systemic treatment in breast cancer
José L Alonso-Romero
Antonio Piero-Madrona
World Journal of Obstetrics and Gynecology, 2013, (02) : 21 - 33
[33] Breast cancer and primary systemic therapy. Results of the Consensus Meeting on the recommendations for pathological examination and histological report of breast cancer specimens in the Marche Region
Santineli, A.
De Nictolis, M.
Mambeli, V.
Ranaldi, R.
Bearzi, I.
Bateli, N.
Marioti, C.
Fabieti, L.
Baldasare, S.
Giusepeti, G. M.
Fabris, G.
PATHOLOGICA, 2011, 103 (05) : 294 - 298
[34] Prognostic and Clinicopathological Correlations of Cell Cycle Marker Expressions before and after the Primary Systemic Therapy of Breast Cancer
Tokes, Timea
Tokes, Anna-Maria
Szentmartoni, Gyongyver
Kiszner, Gergo
Muhl, Dorottya
Molnar, Bela Akos
Kulka, Janina
Krenacs, Tibor
Dank, Magdolna
PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (03) : 1499 - 1510
[35] Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy
Bergen, Elisabeth S.
Berghoff, Anna S.
Rudas, Margaretha
Preusser, Matthias
Bartsch, Rupert
ANTI-CANCER DRUGS, 2015, 26 (05) : 579 - 581
[36] Expression profile of CADM1 and CADM4 in triple negative breast cancer with primary systemic therapy
Kanke, Yasuyuki
Saito, Motonobu
Abe, Noriko
Saito, Katsuharu
Goto, Akiteru
Ohtake, Tohru
Murakami, Yoshinori
Kono, Koji
ONCOLOGY LETTERS, 2019, 17 (01) : 921 - 926
[37] Primary systemic therapy for breast cancer: Does the patient's involvement in decision-making create a new future?
Tokes, Timea
Torgyik, Laszlo
Szentmartoni, Gyoengyver
Somlai, Krisztian
Toth, Andrea
Kulka, Janina
Dank, Magdolna
PATIENT EDUCATION AND COUNSELING, 2015, 98 (06) : 695 - 703
[38] The position and current status of radiation therapy after primary systemic therapy in breast cancer: a national survey-based expert consensus statement
Arenas, M.
Montero, A.
de las Penas, M. D.
Algara, M.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (06) : 582 - 591
[39] The position and current status of radiation therapy after primary systemic therapy in breast cancer: a national survey-based expert consensus statement
M. Arenas
Á. Montero
M. D. de las Peñas
M. Algara
Clinical and Translational Oncology, 2016, 18 : 582 - 591
[40] Surgical Interest of an Accurate Real-World Prediction of Primary Systemic Therapy Response in HER2 Breast Cancers
Sanchez-Mendez, Jose Ignacio
Horstmann, Monica
Mendez, Nieves
Frias, Laura
Moreno, Elisa
Yebenes, Laura
Roca, Ma Jose
Hernandez, Alicia
Marti, Covadonga
CANCERS, 2023, 15 (10)

← 1 2 3 4 5 →